Anti-Caveolin-2 CAV2 Rabbit Monoclonal Antibody

Overview

This product is an anti-CAV2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone FD-3; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF, IP (as provided in the source record). Boster Bio Anti-Caveolin-2 CAV2 Rabbit Monoclonal Antibody catalog # M01574. Tested in WB, IHC, ICC/IF, IP applications. This antibody reacts with Human.

Key elements and design rationale

• Target: CAV2 (Caveolin-2).
• Antibody format: Monoclonal; clone FD-3; isotype Rabbit IgG.
• Host: Rabbit.
• Species reactivity: Human (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

CAV2 (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): May act as a scaffolding protein within caveolar membranes. Interacts ly with G-protein alpha subunits and can functionally regulate their activity. Acts as an accessory protein in conjunction with CAV1 in targeting to lipid rafts and driving caveolae formation. The Ser-36 phosphorylated form has a role in modulating mitosis in endothelial cells. Positive regulator of cellular mitogenesis of the MAPK signaling pathway. Required for the insulin-stimulated nuclear translocation and activation of MAPK1 and STAT3, and the subsequent regulation of cell cycle progression (By similarity). . Reported cellular localization context: Nucleus. Cytoplasm. Golgi apparatus membrane; Peripheral membrane protein. Cell membrane; Peripheral membrane protein. Membrane, caveola; Peripheral membrane protein. Potential hairpin-like structure in the membrane. Membrane protein of caveolae. Tyr-19-phosphorylated form is enriched at sites of cell-cell contact and is translocated to the nucleus in complex with MAPK1 in response to insulin (By similarity). Tyr-27- phosphorylated form is located both in the cytoplasm and plasma membrane. CAV1-mediated Ser-23-phosphorylated form locates to the plasma membrane. Ser-36-phosphorylated form resides in intracellular compartments. . Tissue expression notes (as provided): Expressed in endothelial cells, smooth muscle cells, skeletal myoblasts and fibroblasts. .

Research relevance and current trends

• Research context keywords from the source record include: Calcium Channels,Calcium Signaling,Cancer,Cancer Metabolism,Energy Transfer Pathways,Integration Of Energy,Integration Of Energy Metabolism,Metabolic Signaling Pathway,Metabolic Signaling Pathways,Metabolism,Neuroscience,Neurotransmission,Pathways and Processes,Signal Transduction,Signaling Pathway.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
• Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
• Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.

Workflow ideas (metafield): Validate CAV2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect CAV2 expression by Western blot in cell or tissue lysates, Detect CAV2 in FFPE tissue sections by immunohistochemistry, Localize CAV2 by immunofluorescence/immunocytochemistry in cultured cells, Enrich CAV2 by immunoprecipitation from lysates for downstream analysis

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 75 kDa; calculated MW: 18291 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 75 kDa
• Cellular localization (provided): Nucleus. Cytoplasm. Golgi apparatus membrane; Peripheral membrane protein. Cell membrane; Peripheral membrane protein. Membrane, caveola; Peripheral membrane protein. Potential hairpin-like structure in the membrane. Membrane protein of caveolae. Tyr-19-phosphorylated form is enriched at sites of cell-cell contact and is translocated to the nucleus in complex with MAPK1 in response to insulin (By similarity). Tyr-27- phosphorylated form is located both in the cytoplasm and plasma membrane. CAV1-mediated Ser-23-phosphorylated form locates to the plasma membrane. Ser-36-phosphorylated form resides in intracellular compartments. .
• Tissue details (provided): Expressed in endothelial cells, smooth muscle cells, skeletal myoblasts and fibroblasts. .

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.